Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Tuberculosis

  Free Subscription


Articles published in Clin Infect Dis

Retrieve available abstracts of 159 articles:
HTML format
Text format



Single Articles


    June 2018
  1. SVENSSON EM, Svensson RJ, Te Brake LHM, Boeree MJ, et al
    The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis.
    Clin Infect Dis. 2018;67:34-41.
    PubMed     Text format     Abstract available


    May 2018
  2. GARCIA-PRATS AJ, Draper HR, Finlayson H, Winckler J, et al
    Clinical and cardiac safety of long-term levofloxacin in children treated for multidrug-resistant tuberculosis.
    Clin Infect Dis. 2018 May 16. pii: 4996923. doi: 10.1093.
    PubMed     Text format     Abstract available


    April 2018
  3. XIE YL, Cronin WA, Proschan M, Oatis R, et al
    Transmission of Mycobacterium tuberculosis from patients who are nucleic acid amplification test- negative.
    Clin Infect Dis. 2018 Apr 24. pii: 4984625. doi: 10.1093.
    PubMed     Text format     Abstract available


  4. ZUUR MA, Pasipanodya JG, van Soolingen D, van der Werf TS, et al
    Intermediate Susceptibility Dose-Dependent Breakpoints For High Dose Rifampicin, Isoniazid and Pyrazinamide Treatment in multidrug-resistant tuberculosis Programmes.
    Clin Infect Dis. 2018 Apr 24. pii: 4984540. doi: 10.1093.
    PubMed     Text format     Abstract available


    March 2018
  5. JOHNSON KT, Churchyard GJ, Sohn H, Dowdy DW, et al
    Cost-effectiveness of preventive therapy for tuberculosis with isoniazid and rifapentine versus isoniazid alone in high-burden settings.
    Clin Infect Dis. 2018 Mar 30. pii: 4956926. doi: 10.1093.
    PubMed     Text format     Abstract available


  6. PASIPANODYA JG, Gumbo T
    Individualizing Tuberculosis Treatment: Are Tuberculosis Programs In High Burden Settings Ready For Prime Time Therapeutic Drug Monitoring?
    Clin Infect Dis. 2018 Mar 3. pii: 4919551. doi: 10.1093.
    PubMed     Text format    


    January 2018
  7. YU MC, Chiang CY, Lee JJ, Chien ST, et al
    Treatment outcomes of multidrug-resistant tuberculosis in Taiwan: tackling loss to follow-up.
    Clin Infect Dis. 2018 Jan 31. pii: 4831095. doi: 10.1093.
    PubMed     Text format     Abstract available


  8. MARAIS S, Roos I, Mitha A, Mabusha SJ, et al
    Spinal tuberculosis: Clinicoradiological findings in 274 patients.
    Clin Infect Dis. 2018 Jan 11. pii: 4797620. doi: 10.1093.
    PubMed     Text format     Abstract available


  9. DEGNER NR, Wang JY, Golub JE, Karakousis PC, et al
    Metformin Use Reverses the Increased Mortality Associated With Diabetes Mellitus During Tuberculosis Treatment.
    Clin Infect Dis. 2018;66:198-205.
    PubMed     Text format     Abstract available


    November 2017
  10. KOSER CU, Koeser LA, Dolinger DL
    Limited evidence for need for region-specific, genotypic drug-susceptibility assays for Mycobacterium tuberculosis.
    Clin Infect Dis. 2017 Nov 22. pii: 4647356. doi: 10.1093/cid/cix1042.
    PubMed     Text format    


  11. GRIESEL R, Stewart A, van der Plas H, Sikhondze W, et al
    Optimizing Tuberculosis Diagnosis in HIV-Infected Inpatients Meeting the Criteria of Seriously Ill in the WHO Algorithm.
    Clin Infect Dis. 2017 Nov 6. doi: 10.1093.
    PubMed     Text format     Abstract available


    October 2017
  12. HUAMAN MA, Ticona E, Miranda G, Kryscio RJ, et al
    The Relationship between Latent Tuberculosis Infection and Acute Myocardial Infarction.
    Clin Infect Dis. 2017 Oct 21. doi: 10.1093.
    PubMed     Text format     Abstract available


  13. GUTHRIE JL, Kong C, Roth D, Jorgensen D, et al
    Molecular Epidemiology of Tuberculosis in British Columbia, Canada - A 10-Year Retrospective Study.
    Clin Infect Dis. 2017 Oct 21. doi: 10.1093.
    PubMed     Text format     Abstract available


  14. MARTINEZ L, Zhu L, Castellanos ME, Liu Q, et al
    Glycemic Control and the Prevalence of Tuberculosis Infection: A Population-based Observational Study.
    Clin Infect Dis. 2017 Oct 20. doi: 10.1093.
    PubMed     Text format     Abstract available


  15. OSMAN M, Lee K, Du Preez K, Dunbar R, et al
    Excellent Treatment Outcomes in Children Treated for Tuberculosis Under Routine Operational Conditions in Cape Town, South Africa.
    Clin Infect Dis. 2017;65:1444-1452.
    PubMed     Text format     Abstract available


  16. VANINO E, Tadolini M, Attard L, Po C, et al
    Systematic Tuberculosis Screening in Asylum Seekers in Italy.
    Clin Infect Dis. 2017;65:1407-1409.
    PubMed     Text format     Abstract available


  17. DOBLER CC
    Cumulative Incidence and Incidence Rate Ratio for Estimation of Risk of Tuberculosis in Patients With Cancer.
    Clin Infect Dis. 2017;65:1423.
    PubMed     Text format    


  18. FARHAT MR, Jacobson KR, Franke MF, Kaur D, et al
    Fluoroquinolone Resistance Mutation Detection Is Equivalent to Culture-Based Drug Sensitivity Testing for Predicting Multidrug-Resistant Tuberculosis Treatment Outcome: A Retrospective Cohort Study.
    Clin Infect Dis. 2017;65:1364-1370.
    PubMed     Text format     Abstract available


  19. MCKENNA L, Frick M, Lee C, Namutamba D, et al
    A Community Perspective on the Inclusion of Pregnant Women in Tuberculosis Drug Trials.
    Clin Infect Dis. 2017;65:1383-1387.
    PubMed     Text format     Abstract available


  20. ADU-GYAMFI CG, Snyman T, Hoffmann CJ, Martinson NA, et al
    Plasma Indoleamine 2, 3-Dioxygenase, a Biomarker for Tuberculosis in Human Immunodeficiency Virus-Infected Patients.
    Clin Infect Dis. 2017;65:1356-1358.
    PubMed     Text format     Abstract available


  21. LEE RS, Howden BP
    The Critical Importance of Sampling Fraction to Inferences of Mycobacterium tuberculosis Transmission.
    Clin Infect Dis. 2017 Oct 13. doi: 10.1093.
    PubMed     Text format    


    September 2017
  22. LIN HH, Wu CY, Wang CH, Fu H, et al
    Association of obesity, diabetes, and risk of tuberculosis: two population-based cohorts.
    Clin Infect Dis. 2017 Sep 26. doi: 10.1093.
    PubMed     Text format     Abstract available


  23. SALAZAR-AUSTIN N, Hoffmann J, Cohn S, Mashabela F, et al
    Poor Obstetric and Infant Outcomes in HIV-Infected Pregnant Women with Tuberculosis in South Africa: The Tshepiso Study.
    Clin Infect Dis. 2017 Sep 26. doi: 10.1093.
    PubMed     Text format     Abstract available


  24. SIVRO A, McKinnon LR, Yende-Zuma N, Gengiah S, et al
    Plasma Cytokine Predictors of Tuberculosis Recurrence in Antiretroviral-Treated Human Immunodeficiency Virus-infected Individuals from Durban, South Africa.
    Clin Infect Dis. 2017;65:819-826.
    PubMed     Text format     Abstract available


    August 2017
  25. BACCANI I, Antonelli A, Galano A, Bartalesi F, et al
    Linezolid-resistant Enterococcus faecalis infection following prolonged low-dosage linezolid treatment for multi-drug-resistant tuberculosis.
    Clin Infect Dis. 2017 Aug 20. doi: 10.1093.
    PubMed     Text format    


  26. DRANCOURT M
    Please, no more gastric aspirate to diagnose pulmonary tuberculosis in children.
    Clin Infect Dis. 2017 Aug 19. doi: 10.1093.
    PubMed     Text format    


  27. MUNOZ L, Santin M, Alcaide F, Ruiz-Serrano MJ, et al
    QuantiFERON(R)-TB Gold In-Tube as a confirmatory test for tuberculin skin test in tuberculosis contact tracing: A non-inferiority clinical trial.
    Clin Infect Dis. 2017 Aug 18. doi: 10.1093.
    PubMed     Text format     Abstract available


  28. ARGUELLO PEREZ E, Seo SK, Schneider WJ, Eisenstein C, et al
    Management of Latent Tuberculosis Infection among Healthcare Workers: 10-year Experience at a Single Center.
    Clin Infect Dis. 2017 Aug 17. doi: 10.1093.
    PubMed     Text format     Abstract available


  29. SCHECHTER MC, Bizune D, Kagei M, Machaidze M, et al
    Time to Sputum Culture Conversion and Treatment Outcomes Among Patients with Isoniazid-Resistant Tuberculosis in Atlanta, Georgia.
    Clin Infect Dis. 2017 Aug 3. doi: 10.1093.
    PubMed     Text format     Abstract available


    July 2017
  30. SALINAS JL, Armstrong LR, Silk BJ, Haddad MB, et al
    Factors Associated with All-Cause Mortality among Patients with Multidrug-Resistant Tuberculosis - United States, 1993-2013.
    Clin Infect Dis. 2017 Jul 29. doi: 10.1093.
    PubMed     Text format     Abstract available


  31. FLORIDIA M, Ciccacci F, Andreotti M, Hassane A, et al
    Tuberculosis case finding with combined rapid point of care assays (Xpert(R) MTB/RIF and LAM) in HIV-positive individuals starting antiretroviral treatment in Mozambique.
    Clin Infect Dis. 2017 Jul 23. doi: 10.1093.
    PubMed     Text format     Abstract available


    June 2017
  32. SMITH SE, Pratt R, Trieu L, Barry PM, et al
    Epidemiology of pediatric multidrug-resistant tuberculosis in the United States, 1993-2014.
    Clin Infect Dis. 2017 Jun 19. doi: 10.1093.
    PubMed     Text format     Abstract available


  33. MOORE DP, Higdon MM, Hammitt LL, Prosperi C, et al
    The Incremental Value of Repeated Induced Sputum and Gastric Aspirate Samples for the Diagnosis of Pulmonary Tuberculosis in Young Children With Acute Community-Acquired Pneumonia.
    Clin Infect Dis. 2017;64.
    PubMed     Text format     Abstract available


  34. ROHLWINK UK, Mauff K, Wilkinson KA, Enslin N, et al
    Biomarkers of cerebral injury and inflammation in pediatric tuberculous meningitis.
    Clin Infect Dis. 2017 Jun 9. doi: 10.1093.
    PubMed     Text format     Abstract available


    May 2017
  35. SANDUL AL, Nwana N, Holcombe JM, Lobato MN, et al
    High Rate of Treatment Completion in Program Settings with 12-Dose Weekly Isoniazid and Rifapentine (3HP) for Latent Mycobacterium tuberculosis Infection.
    Clin Infect Dis. 2017 May 30. doi: 10.1093.
    PubMed     Text format     Abstract available


  36. FURIN J, Cox H
    To Test or Not to Test? Ending the Age-Old Debate for Drug-Resistant Tuberculosis.
    Clin Infect Dis. 2017 May 26. doi: 10.1093.
    PubMed     Text format    


  37. AIBANA O, Franke MF, Huang CC, Galea JT, et al
    Impact of Vitamin A and Carotenoids on the Risk of Tuberculosis Progression.
    Clin Infect Dis. 2017 May 20. doi: 10.1093.
    PubMed     Text format     Abstract available


  38. KAWKITINARONG K, Suwanpimolkul G, Kateruttanakul P, Manosuthi W, et al
    Real-Life Clinical Practice of Using the Xpert MTB/RIF Assay in Thailand.
    Clin Infect Dis. 2017;64.
    PubMed     Text format     Abstract available


  39. MANSON AL, Abeel T, Galagan JE, Sundaramurthi JC, et al
    Mycobacterium tuberculosis Whole Genome Sequences From Southern India Suggest Novel Resistance Mechanisms and the Need for Region-Specific Diagnostics.
    Clin Infect Dis. 2017 May 12. doi: 10.1093.
    PubMed     Text format     Abstract available


  40. HARAUSZ EP, Leigh J, Garcia-Prats AJ, Furin J, et al
    Stability of Second-Line Tuberculosis Medications Mixed with Milk or Yogurt.
    Clin Infect Dis. 2017 May 6. doi: 10.1093.
    PubMed     Text format    


  41. SEIFERT M, Georghiou SB, Garfein RS, Catanzaro D, et al
    Impact of fluoroquinolone use on mortality among a cohort of suspected drug-resistant tuberculosis patients.
    Clin Infect Dis. 2017 May 5. doi: 10.1093.
    PubMed     Text format     Abstract available


  42. WALKER NF, Wilkinson KA, Meintjes G, Tezera LB, et al
    Matrix Degradation in Human Immunodeficiency Virus Type 1-Associated Tuberculosis and Tuberculosis Immune Reconstitution Inflammatory Syndrome: A Prospective Observational Study.
    Clin Infect Dis. 2017 May 5. doi: 10.1093.
    PubMed     Text format     Abstract available


  43. HEEMSKERK AD, Nguyen MTH, Dang HTM, Vinh Nguyen CV, et al
    Clinical Outcomes of Patients With Drug-Resistant Tuberculous Meningitis Treated With an Intensified Antituberculosis Regimen.
    Clin Infect Dis. 2017 May 4. doi: 10.1093.
    PubMed     Text format     Abstract available


    April 2017
  44. AUNG HL, Nyunt WW, Fong Y, Cook GM, et al
    First two extensively drug-resistant tuberculosis cases from Myanmar treated with bedaquiline.
    Clin Infect Dis. 2017 Apr 24. doi: 10.1093.
    PubMed     Text format    


  45. PHILLIPS PP
    Setting tuberculosis regimen development on a firm foundation.
    Clin Infect Dis. 2017 Apr 10. doi: 10.1093.
    PubMed     Text format    


  46. BONNETT LJ, Ken-Dror G, Koh G, Davies GR, et al
    Comparing the efficacy of drug regimens for pulmonary tuberculosis: meta-analysis of endpoints in early phase clinical trials.
    Clin Infect Dis. 2017 Apr 10. doi: 10.1093.
    PubMed     Text format     Abstract available


  47. RAOULT D
    Old Antibiotics for Tuberculosis.
    Clin Infect Dis. 2017;64:983.
    PubMed     Text format    


  48. BROGER T, Basu Roy R, Filomena A, Greef CH, et al
    Diagnostic Performance of Tuberculosis-Specific IgG Antibody Profiles in Patients with Presumptive Tuberculosis from Two Continents.
    Clin Infect Dis. 2017;64:947-955.
    PubMed     Text format     Abstract available


    March 2017
  49. JANSSEN S, Schutz C, Ward A, Nemes E, et al
    Mortality in Severe HIV-TB Associates with Innate Immune Activation and Dysfunction of Monocytes.
    Clin Infect Dis. 2017 Mar 24. doi: 10.1093.
    PubMed     Text format     Abstract available


  50. MARKS SM, Mase SR, Bamrah Morris S
    Systematic Review, Meta-Analysis, and Cost Effectiveness of Treatment of Latent Tuberculosis Infection to Reduce Progression to Multidrug-Resistant Tuberculosis.
    Clin Infect Dis. 2017 Mar 14. doi: 10.1093.
    PubMed     Text format     Abstract available


  51. COLLIER D, Iwuji C, Derache A, de Oliveira T, et al
    Virological Outcomes of Second-line Protease Inhibitor-Based Treatment for Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort Analysis.
    Clin Infect Dis. 2017 Mar 13. doi: 10.1093.
    PubMed     Text format     Abstract available


    February 2017
  52. ROCKWOOD N N, Pasipanodya JG, Denti P, Sirgel F, et al
    Concentration-dependent antagonism and culture conversion in pulmonary tuberculosis.
    Clin Infect Dis. 2017 Feb 16. doi: 10.1093.
    PubMed     Text format    


  53. RAVIMOHAN S, Tamuhla N, Nfanyana K, Ni H, et al
    Elevated pre-ART CD39+CD8+ T-cell frequency is associated with early mortality in advanced HIV/TB.
    Clin Infect Dis. 2017 Feb 16. doi: 10.1093.
    PubMed     Text format    


  54. COWAN JF, Chandler AS, Kracen E, Park DR, et al
    Clinical Impact and Cost-effectiveness of Xpert MTB/RIF Testing in Hospitalized Patients With Presumptive Pulmonary Tuberculosis in the United States.
    Clin Infect Dis. 2017;64:482-489.
    PubMed     Text format    


  55. MARAIS BJ, Heemskerk AD, Marais SS, van Crevel R, et al
    Standardized Methods for Enhanced Quality and Comparability of Tuberculous Meningitis Studies.
    Clin Infect Dis. 2017;64:501-509.
    PubMed     Text format    


  56. JOHNSTON JC, Campbell JR, Menzies D
    Effect of intermittency on treatment outcomes in pulmonary tuberculosis: an updated systematic review and meta-analysis.
    Clin Infect Dis. 2017 Feb 14. doi: 10.1093.
    PubMed     Text format    


  57. JACOBSON KR, Barnard M, Kleinman MB, Streicher EM, et al
    Implications of failure to routinely diagnose resistance to second-line drugs in patients with rifampicin-resistant tuberculosis on Xpert MTB/RIF: a multisite observational study.
    Clin Infect Dis. 2017 Feb 12. doi: 10.1093.
    PubMed     Text format    


    January 2017
  58. PROANO A, Bravard MA, Lopez JW, Lee GO, et al
    Dynamics of Cough Frequency in Adults Undergoing Treatment for Pulmonary Tuberculosis.
    Clin Infect Dis. 2017 Jan 25. doi: 10.1093.
    PubMed     Text format     Abstract available


  59. LEWINSOHN DM, Leonard MK, LoBue PA, Cohn DL, et al
    Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children.
    Clin Infect Dis. 2017;64:111-115.
    PubMed     Text format     Abstract available


    December 2016
  60. LEE MR, Huang YP, Kuo YT, Luo CH, et al
    Diabetes mellitus and latent tuberculosis infection: a systemic review and meta-analysis.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  61. CHENG MP, Abou Chakra CN, Yansouni CP, Cnossen S, et al
    Risk of Active Tuberculosis in Patients with Cancer: A Systematic Review and Meta-Analysis.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  62. CHENG MP, Chakra CN, Yansouni CP, Cnossen S, et al
    Risk of Active Tuberculosis in Patients With Cancer: A Systematic Review and Metaanalysis.
    Clin Infect Dis. 2016 Dec 13. doi: 10.1093.
    PubMed     Text format    


  63. COWAN JF, Chandler AS, Kracen E, Park DR, et al
    Clinical Impact and Cost-Effectiveness of Xpert MTB/RIF Testing in Hospitalized Patients with Presumptive Pulmonary Tuberculosis in the United States.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  64. LEWINSOHN DM, Leonard MK, LoBue PA, Cohn DL, et al
    Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  65. VINNARD C, King L, Munsiff S, Crossa A, et al
    The Long-Term Mortality of Tuberculosis Meningitis Patients in New York City: A Cohort Study.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


    November 2016
  66. GUMBO T, Makhene MK, Seddon JA
    Partnerships to Design Novel Regimens to Treat Childhood Tuberculosis, Sui Generis: The Road Ahead.
    Clin Infect Dis. 2016;63.
    PubMed     Text format     Abstract available


  67. SRIVASTAVA S, Deshpande D, Pasipanodya J, Nuermberger E, et al
    Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: Goldilocks.
    Clin Infect Dis. 2016;63.
    PubMed     Text format     Abstract available


  68. DESHPANDE D, Srivastava S, Nuermberger E, Pasipanodya JG, et al
    A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug-Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way.
    Clin Infect Dis. 2016;63.
    PubMed     Text format     Abstract available


  69. DESHPANDE D, Srivastava S, Nuermberger E, Pasipanodya JG, et al
    Concentration-Dependent Synergy and Antagonism of Linezolid and Moxifloxacin in the Treatment of Childhood Tuberculosis: The Dynamic Duo.
    Clin Infect Dis. 2016;63.
    PubMed     Text format     Abstract available


  70. DESHPANDE D, Srivastava S, Pasipanodya JG, Bush SJ, et al
    Linezolid for Infants and Toddlers With Disseminated Tuberculosis: First Steps.
    Clin Infect Dis. 2016;63.
    PubMed     Text format     Abstract available


  71. SRIVASTAVA S, Deshpande D, Pasipanodya JG, Thomas T, et al
    A Combination Regimen Design Program Based on Pharmacodynamic Target Setting for Childhood Tuberculosis: Design Rules for the Playground.
    Clin Infect Dis. 2016;63.
    PubMed     Text format     Abstract available


  72. SWAMINATHAN S, Pasipanodya JG, Ramachandran G, Hemanth Kumar AK, et al
    Drug Concentration Thresholds Predictive of Therapy Failure and Death in Children With Tuberculosis: Bread Crumb Trails in Random Forests.
    Clin Infect Dis. 2016;63.
    PubMed     Text format     Abstract available


  73. SEDDON JA, Makhene MK
    Harnessing Novel Quantitative Pharmacology Approaches to Optimize the Treatment of Children With Tuberculosis.
    Clin Infect Dis. 2016;63.
    PubMed     Text format    


    October 2016
  74. ALFFENAAR JC, Tiberi S, Verbeeck RK, Heysell SK, et al
    Therapeutic Drug Monitoring in Tuberculosis: Practical Application for Physicians.
    Clin Infect Dis. 2016.
    PubMed     Text format    


  75. NAHID P, Dorman SE, Alipanah N, Barry PM, et al
    Executive Summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.
    Clin Infect Dis. 2016;63:853-67.
    PubMed     Text format     Abstract available


    September 2016
  76. YANG JY, Han M, Koh Y, Kim WS, et al
    Effects of Corticosteroids on Critically Ill Pulmonary Tuberculosis Patients with Acute Respiratory Failure: A Propensity Analysis of Mortality.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


    August 2016
  77. NAHID P, Dorman SE, Alipanah N, Barry PM, et al
    Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


    July 2016
  78. CHIANG SS, Starke JR, Miller AC, Cruz AT, et al
    Baseline Predictors of Treatment Outcomes in Children with Multidrug-Resistant Tuberculosis: a Retrospective Cohort Study.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


    June 2016
  79. FUJIWARA PI, Olea-Popelka F
    Why it is important to distinguish Mycobacterium bovis as a causal agent of human tuberculosis.
    Clin Infect Dis. 2016.
    PubMed     Text format    


  80. SCOTT C, Cavanaugh JS, Pratt R, Silk BJ, et al
    Human tuberculosis caused by Mycobacterium bovis in the United States, 2006-2013.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  81. LIENHARDT C, Kraigsley AM, Sizemore CF
    Driving the Way to Tuberculosis Elimination: The Essential Role of Fundamental Research.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


    May 2016
  82. VON DELFT A, Dramowski A, Sifumba Z, Mosidi T, et al
    Exposed, but Not Protected: More Is Needed to Prevent Drug-Resistant Tuberculosis in Healthcare Workers and Students.
    Clin Infect Dis. 2016;62 Suppl 3:S275-80.
    PubMed     Text format     Abstract available


  83. BOULANGER RF, Hunt MR, Benatar SR
    Where Caring Is Sharing: Evolving Ethical Considerations in Tuberculosis Prevention Among Healthcare Workers.
    Clin Infect Dis. 2016;62 Suppl 3:S268-74.
    PubMed     Text format     Abstract available


  84. HATHERILL M, Scriba TJ, Udwadia ZF, Mullerpattan JB, et al
    BCG and New Preventive Tuberculosis Vaccines: Implications for Healthcare Workers.
    Clin Infect Dis. 2016;62 Suppl 3:S262-7.
    PubMed     Text format     Abstract available


  85. TUDOR C, Van der Walt ML, Margot B, Dorman SE, et al
    Occupational Risk Factors for Tuberculosis Among Healthcare Workers in KwaZulu-Natal, South Africa.
    Clin Infect Dis. 2016;62 Suppl 3:S255-61.
    PubMed     Text format     Abstract available


  86. WOUTERS E, Rau A, Engelbrecht M, Uebel K, et al
    The Development and Piloting of Parallel Scales Measuring External and Internal HIV and Tuberculosis Stigma Among Healthcare Workers in the Free State Province, South Africa.
    Clin Infect Dis. 2016;62 Suppl 3:S244-54.
    PubMed     Text format     Abstract available


  87. VAN CUTSEM G, Isaakidis P, Farley J, Nardell E, et al
    Infection Control for Drug-Resistant Tuberculosis: Early Diagnosis and Treatment Is the Key.
    Clin Infect Dis. 2016;62 Suppl 3:S238-43.
    PubMed     Text format     Abstract available


  88. VERKUIJL S, Middelkoop K
    Protecting Our Front-liners: Occupational Tuberculosis Prevention Through Infection Control Strategies.
    Clin Infect Dis. 2016;62 Suppl 3:S231-7.
    PubMed     Text format     Abstract available


  89. EVANS TG, Bekker LG
    Tuberculosis and Healthcare Workers in Underresourced Settings.
    Clin Infect Dis. 2016;62 Suppl 3:S229-30.
    PubMed     Text format    


  90. DINARDO AR, Lange C, Mandalakas AM
    Editorial Commentary: 1, 2, 3 (Years) ... and You're Out: The End of a 123-year Historic Era.
    Clin Infect Dis. 2016;62:1089-91.
    PubMed     Text format    


    March 2016
  91. JONES-LOPEZ EC, Acuna-Villaorduna C, Ssebidandi M, Gaeddert M, et al
    Cough Aerosols of Mycobacterium tuberculosis Predict Incident Tuberculosis Disease in Household Contacts.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  92. BAHR NC, Marais S, Caws M, van Crevel R, et al
    GeneXpert MTB/Rif to Diagnose Tuberculous Meningitis: Perhaps the First Test but not the Last.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  93. MORO RN, Borisov A, Saukkonen J, Khan A, et al
    Factors Associated with Non-completion of Latent Tuberculosis Infection Treatment: Experience from the PREVENT TB Trial in the United States and Canada.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  94. GARCIA MJ, Lopez MR
    Do we have strategies to improve the preventive treatment of Latent Tuberculosis Infection?
    Clin Infect Dis. 2016.
    PubMed     Text format    


  95. BARNER A, Frank C, Shipton L
    Tooth Discoloration in a Patient With Multidrug-Resistant Tuberculosis.
    Clin Infect Dis. 2016;62:664-5.
    PubMed     Text format    



  96. Tooth Discoloration in a Patient With Multidrug-Resistant Tuberculosis.
    Clin Infect Dis. 2016;62:617.
    PubMed     Text format    


    February 2016
  97. TIBERI S, Sotgiu G, D'Ambrosio L, Centis R, et al
    Comparison of effectiveness and safety of imipenem/clavulanate added to an optimised background regimen (OBR) versus OBR controls regimens in the treatment of multidrug and extensively drug-resistant tuberculosis.
    Clin Infect Dis. 2016.
    PubMed     Text format    


  98. THERON G, Venter R, Calligaro G, Smith L, et al
    Xpert MTB/RIF Results in Patients With Previous Tuberculosis: Can We Distinguish True From False Positive Results?
    Clin Infect Dis. 2016 Feb 16. pii: civ1223.
    PubMed     Text format     Abstract available


  99. DETJEN AK, Walters E
    Improving Children's Access to New Tuberculosis Diagnostic Tools Starts With the Collection of Appropriate Specimens.
    Clin Infect Dis. 2016.
    PubMed     Text format    


  100. MARCY O, Ung V, Goyet S, Borand L, et al
    Performance of Xpert MTB/RIF and Alternative Specimen Collection Methods for the Diagnosis of Tuberculosis in HIV-Infected Children.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  101. FIRNHABER C, Kendall MA, Wu X, Mazurek GH, et al
    Evaluation of Xpert MTB/RIF to identify pulmonary tuberculosis in tuberculosis suspects from low and higher prevalence settings compared to acid fast smear and culture.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


    January 2016
  102. SHAH NS, Yuen CM, Heo M, Tolman AW, et al
    Reply to Hong-min et al.
    Clin Infect Dis. 2016;62:267-8.
    PubMed     Text format    


  103. HSU DC, Faldetta KF, Pei L, Sheikh V, et al
    A Paradoxical Treatment for a Paradoxical Condition: Infliximab Use in Three Cases of Mycobacterial IRIS.
    Clin Infect Dis. 2016;62:258-61.
    PubMed     Text format     Abstract available


  104. FOX GJ, Mitnick CD, Benedetti A, Chan ED, et al
    Surgery as an adjunctive treatment for multi-drug resistant tuberculosis: an individual patient data meta-analysis.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


    December 2015
  105. GUPTA A, Mathad JS, Abdel-Rahman SM, Albano JD, et al
    Towards Earlier Inclusion of Pregnant and Postpartum Women in TB Drug Trials: Consensus Statements from an International Expert Panel.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


  106. XIE YL, Rosen LB, Sereti I, Barber DL, et al
    Severe paradoxical reaction during treatment of disseminated tuberculosis in a patient with neutralizing anti-IFNgamma autoantibodies.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


    November 2015
  107. RAVIMOHAN S, Tamuhla N, Nfanyana K, Steenhoff AP, et al
    Robust reconstitution of TB-specific polyfunctional CD4+ T-cell responses and rising systemic IL-6 in paradoxical TB-IRIS.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


  108. AKKERMAN OW, Odish OF, Bolhuis MS, de Lange WC, et al
    Pharmacokinetics of bedaquiline in cerebrospinal fluid and serum in multidrug-resistant tuberculous meningitis.
    Clin Infect Dis. 2015.
    PubMed     Text format    


  109. LANOIX JP, Chaisson RE, Nuermberger EL
    Shortening tuberculosis treatment with fluoroquinolones: lost in translation?
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


    October 2015
  110. CEGIELSKI JP, Kurbatova E, van der Walt M, Brand J, et al
    Multidrug-Resistant Tuberculosis Treatment Outcomes in Relation to Treatment, Initial and Acquired Second-Line Drug Resistance.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


  111. SCHITO M, Maeurer M, Kim P, Hanna D, et al
    Translating the Tuberculosis Research Agenda: Much Accomplished, but Much More to Be Done.
    Clin Infect Dis. 2015;61Suppl 3:S95-S101.
    PubMed     Text format     Abstract available


  112. RAO M, Valentini D, Poiret T, Dodoo E, et al
    B in TB: B Cells as Mediators of Clinically Relevant Immune Responses in Tuberculosis.
    Clin Infect Dis. 2015;61Suppl 3:S225-34.
    PubMed     Text format     Abstract available


  113. MAHON RN, Hafner R
    Immune Cell Regulatory Pathways Unexplored as Host-Directed Therapeutic Targets for Mycobacterium tuberculosis: An Opportunity to Apply Precision Medicine Innovations to Infectious Diseases.
    Clin Infect Dis. 2015;61Suppl 3:S200-16.
    PubMed     Text format     Abstract available


  114. SEDDON JA, McKenna L, Shah T, Kampmann B, et al
    Recent Developments and Future Opportunities in the Treatment of Tuberculosis in Children.
    Clin Infect Dis. 2015;61Suppl 3:S188-99.
    PubMed     Text format     Abstract available


  115. GRAHAM SM, Cuevas LE, Jean-Philippe P, Browning R, et al
    Clinical Case Definitions for Classification of Intrathoracic Tuberculosis in Children: An Update.
    Clin Infect Dis. 2015;61Suppl 3:S179-87.
    PubMed     Text format     Abstract available


  116. ZAR HJ, Workman LJ, Little F, Nicol MP, et al
    Diagnosis of Pulmonary Tuberculosis in Children: Assessment of the 2012 National Institutes of Health Expert Consensus Criteria.
    Clin Infect Dis. 2015;61Suppl 3:S173-8.
    PubMed     Text format     Abstract available


  117. NICOL MP, Gnanashanmugam D, Browning R, Click ES, et al
    A Blueprint to Address Research Gaps in the Development of Biomarkers for Pediatric Tuberculosis.
    Clin Infect Dis. 2015;61Suppl 3:S164-72.
    PubMed     Text format     Abstract available


  118. WALLIS RS, Peppard T
    Early Biomarkers and Regulatory Innovation in Multidrug-Resistant Tuberculosis.
    Clin Infect Dis. 2015;61Suppl 3:S160-3.
    PubMed     Text format     Abstract available


  119. HAMILTON CD, Swaminathan S, Christopher DJ, Ellner J, et al
    RePORT International: Advancing Tuberculosis Biomarker Research Through Global Collaboration.
    Clin Infect Dis. 2015;61Suppl 3:S155-9.
    PubMed     Text format     Abstract available


  120. KNIGHT GM, Colijn C, Shrestha S, Fofana M, et al
    The Distribution of Fitness Costs of Resistance-Conferring Mutations Is a Key Determinant for the Future Burden of Drug-Resistant Tuberculosis: A Model-Based Analysis.
    Clin Infect Dis. 2015;61Suppl 3:S147-54.
    PubMed     Text format     Abstract available


  121. STARKS AM, Aviles E, Cirillo DM, Denkinger CM, et al
    Collaborative Effort for a Centralized Worldwide Tuberculosis Relational Sequencing Data Platform.
    Clin Infect Dis. 2015;61Suppl 3:S141-6.
    PubMed     Text format     Abstract available


  122. LANGLEY I, Squire SB, Dacombe R, Madan J, et al
    Developments in Impact Assessment of New Diagnostic Algorithms for Tuberculosis Control.
    Clin Infect Dis. 2015;61Suppl 3:S126-34.
    PubMed     Text format     Abstract available


  123. DOMINIQUE JK, Ortiz-Osorno AA, Fitzgibbon J, Gnanashanmugam D, et al
    Implementation of HIV and Tuberculosis Diagnostics: The Importance of Context.
    Clin Infect Dis. 2015;61Suppl 3:S119-25.
    PubMed     Text format     Abstract available


  124. SCHITO M, Migliori GB, Fletcher HA, McNerney R, et al
    Perspectives on Advances in Tuberculosis Diagnostics, Drugs, and Vaccines.
    Clin Infect Dis. 2015;61Suppl 3:S102-18.
    PubMed     Text format     Abstract available


    September 2015
  125. HONG-MIN W, Xiao-Hong Z, Jing W
    Drug-resistant tuberculosis and the prevention of ongoing transmission.
    Clin Infect Dis. 2015.
    PubMed     Text format    


  126. STENNIS N, Burzynski J, Herbert C, Nilsen D, et al
    Treatment for tuberculosis infection with three months of rifapentine and isoniazid in New York City Health Department clinics.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


    August 2015
  127. ROMERO K, Clay R, Hanna D
    Strategic Regulatory Evaluation and Endorsement of the Hollow Fiber Tuberculosis System as a Novel Drug Development Tool.
    Clin Infect Dis. 2015;61 Suppl 1:S5-9.
    PubMed     Text format     Abstract available


  128. GUMBO T, Pasipanodya JG, Romero K, Hanna D, et al
    Forecasting Accuracy of the Hollow Fiber Model of Tuberculosis for Clinical Therapeutic Outcomes.
    Clin Infect Dis. 2015;61 Suppl 1:S25-31.
    PubMed     Text format     Abstract available


  129. GUMBO T, Pasipanodya JG, Nuermberger E, Romero K, et al
    Correlations Between the Hollow Fiber Model of Tuberculosis and Therapeutic Events in Tuberculosis Patients: Learn and Confirm.
    Clin Infect Dis. 2015;61 Suppl 1:S18-24.
    PubMed     Text format     Abstract available


  130. PASIPANODYA JG, Nuermberger E, Romero K, Hanna D, et al
    Systematic Analysis of Hollow Fiber Model of Tuberculosis Experiments.
    Clin Infect Dis. 2015;61 Suppl 1:S10-7.
    PubMed     Text format     Abstract available


  131. CAVALERI M, Manolis E
    Hollow Fiber System Model for Tuberculosis: The European Medicines Agency Experience.
    Clin Infect Dis. 2015;61 Suppl 1:S1-4.
    PubMed     Text format     Abstract available


    July 2015
  132. TIEN V, Robilotti E, Callister D, Subramanian A, et al
    Tolerability of Fluoroquinolones in Management of Latent Tuberculosis in Liver Transplant Candidates.
    Clin Infect Dis. 2015.
    PubMed     Text format    


  133. DASKAPAN A, Stienstra Y, Akkerman OW, de Lange WC, et al
    The Never Ending Struggle Against Development of Drug Resistance.
    Clin Infect Dis. 2015;61:137-8.
    PubMed     Text format    


  134. NARENDRAN G, Swaminathan S
    Reply to Daskapan et al.
    Clin Infect Dis. 2015;61:138-9.
    PubMed     Text format    


    June 2015
  135. TABURET AM, Sauvageon H, Grinsztejn B, Assuied A, et al
    Pharmacokinetics of Raltegravir in HIV-infected Patients on Rifampicin-Based Antitubercular Therapy.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


  136. PODANY AT, Bao Y, Swindells S, Chaisson RE, et al
    Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


  137. SHANN F
    Different strains of Bacillus Calmette-Guerin vaccine have very different effects on tuberculosis and on unrelated infections.
    Clin Infect Dis. 2015.
    PubMed     Text format    


  138. BIALVAEI AZ, Kafil HS, Asgharzadeh M
    Role of Treatment Cost on Transmission of Multidrug-Resistant Tuberculosis Into Iran.
    Clin Infect Dis. 2015.
    PubMed     Text format    


    May 2015
  139. MAKHARIA GK, Ghoshal UC, Ramakrishna BS, Agnihotri A, et al
    Intermittent supervised therapy for abdominal tuberculosis: A multicenter randomized controlled trial comparing 6 months versus 9 months duration of therapy.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


  140. CHOW FC, Glaser CA, Sheriff H, Xia D, et al
    Use of clinical and neuroimaging characteristics to distinguish temporal lobe herpes simplex encephalitis from its mimics.
    Clin Infect Dis. 2015;60:1377-83.
    PubMed     Text format     Abstract available


    April 2015
  141. CHAISSON LH, Davis JL
    Reply to Baker and Holtom.
    Clin Infect Dis. 2015;60:1288-9.
    PubMed     Text format    


  142. BASTOS ML, Menzies D
    Reply to Wang and Zhang.
    Clin Infect Dis. 2015;60:1286-7.
    PubMed     Text format    


    March 2015
  143. SHIVAKOTI R, Yang WT, Gupte N, Berendes S, et al
    Concurrent anemia and elevated CRP predicts HIV clinical treatment failure, including TB, post-antiretroviral therapy initiation.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


  144. RAOULT D
    Extensively drug-resistant tuberculosis: you can teach an old dog new tricks.
    Clin Infect Dis. 2015;60:971.
    PubMed     Text format    


  145. SOMAN R, Shetty A, Rodrigues C
    We must halt the progression of multidrug-resistant tuberculosis to extensively drug-resistant tuberculosis, no matter what the cost.
    Clin Infect Dis. 2015;60:968.
    PubMed     Text format    


  146. ALFFENAAR JW, Gumbo T, Aarnoutse RE
    Acquired drug resistance: we can do more than we think!
    Clin Infect Dis. 2015;60:969-70.
    PubMed     Text format    


  147. METCALFE JZ, Vittinghoff E, Hopewell PC
    Analysis of Green Light Committee implementation and acquisition of second-line drug resistance.
    Clin Infect Dis. 2015;60:970.
    PubMed     Text format    


    January 2015
  148. KERKHOFF AD, Lawn SD
    Iron Replacement Therapy and Anemia Associated with Chronic Infectious Diseases in Sub-Saharan Africa.
    Clin Infect Dis. 2015.
    PubMed     Text format    


    October 2014
  149. MCMULLEN SE, Pegues DA, Shofer FS, Sheller AC, et al
    Reply to Islam et al and Mendy et al.
    Clin Infect Dis. 2014;59:1189-90.
    PubMed     Text format    


  150. VISSER DH, Solomons RS, Ronacher K, van Well GT, et al
    Host immune response to tuberculous meningitis.
    Clin Infect Dis. 2014.
    PubMed     Text format     Abstract available


    September 2014
  151. DENKINGER CM, Pai M
    Reply to El Sahly.
    Clin Infect Dis. 2014;59:912.
    PubMed     Text format    


    August 2014
  152. NARENDRAN G, Menon PA, Venkatesan P, Vijay K, et al
    Acquired Rifampicin Resistance in Thrice-Weekly TB Therapy: Impact of HIV and Antiretroviral Therapy.
    Clin Infect Dis. 2014.
    PubMed     Text format     Abstract available


  153. SOLOMONS RS, Wessels M, Visser DH, Donald PR, et al
    Uniform research case definition criteria differentiate tuberculous and bacterial meningitis in children.
    Clin Infect Dis. 2014.
    PubMed     Text format     Abstract available


  154. MARAIS S, Wilkinson KA, Lesosky M, Coussens AK, et al
    Neutrophil-associated central nervous system inflammation in tuberculous meningitis immune reconstitution inflammatory syndrome.
    Clin Infect Dis. 2014.
    PubMed     Text format     Abstract available


  155. CHAISSON LH, Roemer M, Cantu D, Haller B, et al
    Impact of GeneXpert MTB/RIF on Triage of Respiratory Isolation Rooms for Inpatients with Presumed TB: A Hypothetical Trial.
    Clin Infect Dis. 2014.
    PubMed     Text format     Abstract available


    July 2014
  156. KIM CH, Lee J
    Reply to Hong et al.
    Clin Infect Dis. 2014;59:142-3.
    PubMed     Text format    


    April 2014
  157. SOHN H, Aero AD, Menzies D, Behr M, et al
    Xpert MTB/RIF testing in a low tuberculosis incidence, high-resource setting: limitations in accuracy and clinical impact.
    Clin Infect Dis. 2014;58:970-6.
    PubMed     Text format     Abstract available


  158. SALFINGER M
    Molecular laboratory testing for tuberculosis: innovators, early adopters, or laggards?
    Clin Infect Dis. 2014;58:977-9.
    PubMed     Text format    


  159. SYRIGOU E, Gkiozos I, Dannos I, Grapsa D, et al
    Giant tuberculin reaction associated with the homeopathic drug tuberculinum: a case report.
    Clin Infect Dis. 2014;58:e119-21.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Tuberculosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: